Molecular pathology of non-small cell carcinoma

被引:11
|
作者
Yatabe, Yasushi [1 ,2 ]
机构
[1] Natl Canc Ctr, Dept Diagnost Pathol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Diagnost Pathol, 5-1-1 Tsukiji, Chuo Ku, Tokyo 1040045, Japan
基金
日本学术振兴会;
关键词
immune check-point inhibitors; lung cancer; molecular pathogenesis; oncogene addiction; two-compartment model; FACTOR-RECEPTOR GENE; IMMUNE CHECKPOINT INHIBITORS; TUMOR MUTATION BURDEN; LUNG-CANCER; EGFR MUTATIONS; TYROSINE KINASE; CLINICOPATHOLOGICAL FEATURES; RET REARRANGEMENTS; CLINICAL-FEATURES; PD-L1; EXPRESSION;
D O I
10.1111/his.15080
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Currently, lung cancer is treated by the highest number of therapeutic options and the benefits are based on multiple large-scale sequencing studies, translational research and new drug development, which has promoted our understanding of the molecular pathology of lung cancer. According to the driver alterations, different characteristics have been revealed, such as differences in ethnic prevalence, median age and alteration patterns. Consequently, beyond traditional chemoradiotherapy, molecular-targeted therapy and treatment with immune check-point inhibitors (ICI) also became available major therapeutic options. Interestingly, clinical results suggest that the recently established therapies target distinct lung cancer proportions, particularly between the EGFR/ALK and PD-1/PD-L1-positive subsets, e.g. the kinase inhibitors target driver mutation-positive tumours, whereas driver mutation-negative tumours respond to ICI treatment. These therapeutic efficacy-related differences might be explained by the molecular pathogenesis of lung cancer. Addictive driver mutations promote tumour formation with powerful transformation performance, resulting in a low tumour mutation burden, reduced immune surveillance, and subsequent poor response to ICIs. In contrast, regular tobacco smoke exposure repeatedly injures the proximal airway epithelium, leading to accumulated genetic alterations. In the latter pathway, overgrowth due to alteration and immunological exclusion against neoantigens is initially balanced. However, tumours could be generated from certain clones that outcompete immunological exclusion and outgrow the others. Consequently, this cancer type responds to immune check-point treatment. These pathogenic differences are explained well by the two-compartment model, focusing upon the anatomical and functional composition of distinct cellular components between the terminal respiratory unit and the air-conducting system. Two-compartment model in the putative molecular pathogenesis of lung cancer. The accumulation of genetic alterations with escaping immune surveillance is a key factor for tumours from the air-conducting system under the strong influence of tobacco smoke, whereas oncogene-addicted adenocarcinomas are driven by a single oncogenic mutation with powerful transformation activity.image
引用
收藏
页码:50 / 66
页数:17
相关论文
共 50 条
  • [21] Molecular characteristics of metastatic non-small cell lung carcinoma (NSCLC) to the brain
    Saad, A. F.
    Pinkus, G. S.
    Pinkus, J. L.
    Sugarbaker, D.
    Chirieoc, L. R.
    LABORATORY INVESTIGATION, 2008, 88 : 323A - 323A
  • [22] Molecular characteristics of metastatic non-small cell lung carcinoma (NSCLC) to the brain
    Saad, A. G.
    Pinkus, G. S.
    Pinkus, J. L.
    Sugarbaker, D.
    Chirieac, L. R.
    MODERN PATHOLOGY, 2008, 21 : 323A - 323A
  • [23] Surgical resection of non-small cell carcinoma after treatment for small cell carcinoma
    Smythe, WR
    Estrera, AL
    Swisher, SG
    Merriman, KW
    Walsh, GL
    Putnam, JB
    Vaporciyan, AA
    Roth, JA
    ANNALS OF THORACIC SURGERY, 2001, 71 (03): : 962 - 966
  • [24] Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives
    Hofman, Paul
    Rouleau, Etienne
    Sabourin, Jean-Christophe
    Denis, Marc
    Deleuze, Jean-Francois
    Barlesi, Fabrice
    Laurent-Puig, Pierre
    CANCER CYTOPATHOLOGY, 2020, 128 (09) : 601 - 610
  • [25] Pulmonary Non-Small Cell Carcinoma With Morphologic Features of Adenocarcinoma or "Non-Small Cell Carcinoma Favor Adenocarcinoma" in Cytologic Specimens Share Similar Clinical and Molecular Genetic Characteristics
    Hutchings, Danielle
    Maleki, Zahra
    Rodriguez, Erika F.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2018, 149 (06) : 514 - 521
  • [26] Non-Small Cell Lung Carcinoma Brain Metastases with Squamous Cell Carcinoma or Small Cell Carcinoma Histology
    Cowan, M. L.
    Westra, W. H.
    Illei, P. B.
    MODERN PATHOLOGY, 2014, 27 : 476A - 476A
  • [27] Non-Small Cell Lung Carcinoma Brain Metastases with Squamous Cell Carcinoma or Small Cell Carcinoma Histology
    Cowan, M. L.
    Westra, W. H.
    Illei, P. B.
    LABORATORY INVESTIGATION, 2014, 94 : 476A - 476A
  • [28] Non-small cell lung cancer-pathology and biology
    Wittersheim, Maike
    Schallenberg, S.
    Buettner, R.
    ONKOLOGE, 2018, 24 (12): : 958 - 966
  • [29] Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small Cell Lung Carcinoma
    Carter, Jamal H.
    Miller, James A.
    Maleki, Zahra
    LABORATORY INVESTIGATION, 2016, 96 : 94A - 94A
  • [30] Clinicopathological and Molecular Study of Peritoneal Carcinomatosis Associated with Non-Small Cell Lung Carcinoma
    Nassereddine, Hussein
    Sannier, Aurelie
    Brosseau, Solenn
    Rodier, Jean-Michel
    Khalil, Antoine
    Msika, Simon
    Danel, Claire
    Couvelard, Anne
    Theou-Anton, Nathalie
    Cazes, Aurelie
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2795 - 2800